The IL-13 Story in Atopic Dermatitis: Characterizing Pathways and Therapeutic Performance

The presentation positioned interleukin-13 (IL-13) as a dominant cytokine in atopic dermatitis, driving inflammation, barrier dysfunction, dysbiosis, and chronic itch. Unlike IL-4, IL-13 remains elevated even in nonlesional, normal-appearing skin, helping explain persistent disease activity between flares. IL-13 levels closely correlate with both disease severity and chronicity, and its direct role in itch signaling makes it a key therapeutic target in AD.

Differences among IL-13–directed biologics were reviewed, including dupilumab, which blocks IL-4 and IL-13 signaling via IL-4Rα, and the IL-13 - specific agents tralokinumab and lebrikizumab, which bind distinct sites on the IL-13 cytokine. Notably, lebrikizumab demonstrates substantially higher binding affinity for IL-13 and offers dosing flexibility, with data supporting every-four-week and even extended every-eight-week maintenance dosing in select patients. Age approvals also vary, with dupilumab approved down to infancy, while tralokinumab and lebrikizumab are approved for adolescents and adults.

The session addressed real-world management challenges, including treatment switching. Data from the ADapt trial showed that patients discontinuing dupilumab due to ocular or facial adverse events experienced effective disease control after switching to lebrikizumab without recurrence of those side effects. Emerging evidence also suggests JAK inhibitors may be particularly helpful for resolving dupilumab-associated ocular and facial inflammation. Looking ahead, several next-generation IL-13 - targeted therapies, including trispecific agents, are in development, signaling continued refinement of precision therapy in AD.